Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Hepatic transcriptomic alterations for N,N-dimethyl-p-toluidine (DMPT) and p-toluidine after 5-day exposure in rats

ABSTRACT: To identify liver transcripts differentially expressed due to treatment with N, N-dimethyl-p-toluidine (DMPT) and p-toluidine, we collected RNA during the from male F344/N rats exposed to 0, 1, 6, 20, 60 or 120 mg/kg DMPT (or p-toluidine), 5 days after exposure for animals 5-6 weeks of age. These samples were interrogated with the Affymetrix Rat Genome 230 2.0 GeneChip Array. A total of 511 gene transcripts were differentially expressed due to DMPT treatment and 354 gene transcripts were differentially expressed due to p-toluidine treatment (false discovery rate (FDR) < 0.05).

ORGANISM(S): Rattus norvegicus

PROVIDER: GSE100502 | GEO | 2017/06/27

SECONDARY ACCESSION(S): PRJNA391963

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Molecular Changes in the Nasal Cavity after 5 days of N, N-dimethyl-p-toluidine Exposure

2016-08-11 | GSE85454 | GEO

Molecular Changes in the Nasal Cavity after 5 days of N, N-dimethyl-p-toluidine Exposure

Project description:To identify nasal cavity transcripts differentially expressed due to treatment with N, N-dimethyl-p-toluidine (DMPT), we collected RNA during the from male F344/N rats exposed to 120 mg/kg DMPT, 5 days after DMPT exposure for animals 5-6 weeks of age. These samples were interrogated with the Affymetrix Rat Genome 230 2.0 GeneChip Array. A total of 2,561 gene transcripts were differentially expressed due to DMPT treatment (false discovery rate (FDR) < 0.05). There were 2 groups and 5x replication for each group, for 10 total samples. The groups were (1) DMPT and (2) vehicle control. We compared vehicle control vs DMPT using ORIOGEN software. The permutation based p-values for each test were significant for FDRâ¤5%.

2016-08-11 | E-GEOD-85454 | biostudies-arrayexpress

E-GEOD-47346

Project description:Identification of differentially expressed genes due to LBH589 treatment in aromatase inhibitor-resistant tumors

2015-07-13 | E-GEOD-47346 | ExpressionAtlas

Homo sapiens

Project description:Differentially expressed transcripts in SLE blood monocytes

| PRJNA203040 | ENA

Homo sapiens

Project description:Identification of differentially expressed genes due to LBH589 treatment in aromatase inhibitor-resistant tumors

| PRJNA205203 | ENA

Hepatic transcriptomic alterations for polybrominated diphenyl ether 47 (PBDE47) after 5-day exposure in rats

Project description:To identify liver transcripts differentially expressed due to treatment with polybrominated diphenyl ether 47 (PBDE47), we collected RNA from male Harlan Sprague Dawley rats exposed to 0, 0.0485, 0.485, 4.85, 48.5 or 485 mg/kg PBDE47, 5 days after exposure for animals 7 weeks of age. These samples were interrogated with the Affymetrix Rat Genome 230 2.0 GeneChip array. A total of 44,28,111,999, and 3195 gene transcripts were differentially expressed due to PBDE47 treatment after exposure to 0.0485, 0.485, 4.85, 48.5 or 485 mg/kg PBDE47 (false discovery rate (FDR) < 0.05).

2020-07-15 | GSE153360 | GEO

Hepatic transcriptomic alterations for bis(2-ethylhexyl) tetrabromophthalate (TBPH) after 5-day exposure in rats

Project description:To identify liver transcripts differentially expressed due to treatment with bis(2-ethylhexyl) tetrabromophthalate (TBPH), we collected RNA from male Harlan Sprague Dawley rats exposed to 0, 0.07, 0.71, 7.06, 70.6 or 706 mg/kg TBPH, 5 days after exposure for animals 7 weeks of age. These samples were interrogated with the Affymetrix Rat Genome 230 2.0 GeneChip array. A total of 0,0,0,0, and 0 gene transcripts were differentially expressed due to TBPH treatment after exposure to 0.07, 0.71, 7.06, 70.6 or 706 mg/kg TBPH (false discovery rate (FDR) < 0.05).

2020-07-15 | GSE153365 | GEO

Hepatic transcriptomic alterations for tetrabromobisphenol A-bis(2,3-dibromopropyl ether) (TBBPA-DBPE) after 5-day exposure in rats

Project description:To identify liver transcripts differentially expressed due to treatment with tetrabromobisphenol A-bis(2,3-dibromopropyl ether) (TBBPA-DBPE), we collected RNA from male Harlan Sprague Dawley rats exposed to 0, 0.1, 0.94, 9.4, 94.3 or 943 mg/kg TBBPA.DBPE, 5 days after exposure for animals 7 weeks of age. These samples were interrogated with the Affymetrix Rat Genome 230 2.0 GeneChip array. A total of 0,0,0,0,0, and 0 gene transcripts were differentially expressed due to TBBPA.DBPE treatment after exposure to 0.1, 0.94, 9.4, 94.3 or 943 mg/kg TBBPA.DBPE (false discovery rate (FDR) < 0.05).

2020-07-15 | GSE153363 | GEO

Hepatic transcriptomic alterations for 2-ethylhexyl-2,3,4,5-tetrabromobenzoate (TBB) after 5-day exposure in rats

Project description:To identify liver transcripts differentially expressed due to treatment with 2-ethylhexyl-2,3,4,5-tetrabromobenzoate (TBB), we collected RNA from male Harlan Sprague Dawley rats exposed to 0, 0.05, 0.55, 5.50, 55 or 550 mg/kg TBB, 5 days after exposure for animals 7 weeks of age. These samples were interrogated with the Affymetrix Rat Genome 230 2.0 GeneChip array. A total of 1,0,2,2, and 66 gene transcripts were differentially expressed due to TBB treatment after exposure to 0.05, 0.55, 5.50, 55 or 550 mg/kg TBB (false discovery rate (FDR) < 0.05).

2020-07-15 | GSE153361 | GEO

Hepatic transcriptomic alterations for hexachlorocyclopentadienyl-dibromocyclooctane (HCDBCO) after 5-day exposure in rats

Project description:To identify liver transcripts differentially expressed due to treatment with hexachlorocyclopentadienyl-dibromocyclooctane (HCDBCO), we collected RNA from male Harlan Sprague Dawley rats exposed to 0, 0.05, 0.54, 5.41, 54.1 or 541 mg/kg HCDBCO, 5 days after exposure for animals 7 weeks of age. These samples were interrogated with the Affymetrix Rat Genome 230 2.0 GeneChip array. A total of 0,0,0,12, and 19 gene transcripts were differentially expressed due to HCDBCO treatment after exposure to 0.05, 0.54, 5.41, 54.1 or 541 mg/kg HCDBCO (false discovery rate (FDR) < 0.05).

2020-07-15 | GSE153359 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data